This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
by Kanishka Das
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
REGNPositive Net Change BEAMPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
TEVAPositive Net Change ANIPPositive Net Change AMRXPositive Net Change VTRSPositive Net Change
biotechs medical
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
by Zacks Equity Research
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
GSKPositive Net Change ALKSPositive Net Change GILDPositive Net Change FOLDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
ANIPPositive Net Change ADMAPositive Net Change KODNegative Net Change ARQTNegative Net Change
biotechnology biotechs earnings medical
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
by Zacks Equity Research
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
BMYPositive Net Change ALKSPositive Net Change FOLDPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
by Ekta Bagri
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
NVSPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Undervalued Stocks That Are Poised for Growth in November
by Kinjel Shah
Five undervalued picks - including StoneCo and MillerKnoll - shine with strong growth prospects and low price-to-book ratios this November.
GLDDPositive Net Change ENSPositive Net Change STNEPositive Net Change KROSPositive Net Change MLKNPositive Net Change
batteries biotechs computers construction
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
by Sundeep Ganoria
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
by Ahan Chakraborty
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
ALKSPositive Net Change FOLDPositive Net Change CRMDNegative Net Change IMVTPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
ANIPPositive Net Change ADMAPositive Net Change EDITNegative Net Change ARQTNegative Net Change
biotechnology biotechs earnings gene-editing medical pharmaceuticals
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
ALKSPositive Net Change VRTXPositive Net Change CRMDNegative Net Change CRSPNegative Net Change
biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
by Sundeep Ganoria
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
ASNDNegative Net Change AUTLPositive Net Change IMRXNegative Net Change ANROPositive Net Change
biotechs earnings medical
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
by Ahan Chakraborty
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
by Zacks Equity Research
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
ALKSPositive Net Change ANIPPositive Net Change CRMDNegative Net Change IOVANegative Net Change
biotechs earnings medical
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
by Zacks Equity Research
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
BIIBPositive Net Change ALKSPositive Net Change DNLIPositive Net Change TAKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
by Zacks Equity Research
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
SNYPositive Net Change NVAXPositive Net Change ANIPPositive Net Change ARQTNegative Net Change
biotechs earnings
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
by Zacks Equity Research
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
ALKSPositive Net Change ANIPPositive Net Change CRMDNegative Net Change ALLONegative Net Change
biotechs earnings medical
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
by Zacks Equity Research
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
PBYINegative Net Change ANIPPositive Net Change SNDXNegative Net Change ARQTNegative Net Change
biotechs earnings
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
LLYPositive Net Change NKTRPositive Net Change ANIPPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
by Zacks Equity Research
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
REGNPositive Net Change ANIPPositive Net Change ACADPositive Net Change NTLANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
ALKSPositive Net Change ANIPPositive Net Change CRMDNegative Net Change RVMDPositive Net Change
biotechs earnings medical